These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30667173)

  • 1. Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post-marketing surveillance study in Japan.
    Fazeli Farsani S; Taniguchi A; Ikeda R; Brodovicz KG; Bartels DB
    J Diabetes Investig; 2019 Sep; 10(5):1246-1253. PubMed ID: 30667173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
    J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
    J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
    J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
    Inagaki N; Nishimoto T; Nishiya Y; Nitta D
    Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study.
    Takahashi H; Nishimura R; Tsujino D; Utsunomiya K
    J Diabetes Investig; 2019 May; 10(3):714-722. PubMed ID: 30171747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
    Ito T; Naito Y; Shimmoto N; Ochiai K; Hayashi N; Okamura T
    Expert Opin Drug Saf; 2021 Mar; 20(3):363-372. PubMed ID: 33269625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
    Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study.
    Kaku K; Nakayama Y; Yabuuchi J; Naito Y; Kanasaki K
    Expert Opin Drug Saf; 2023; 22(9):819-832. PubMed ID: 37194266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study.
    Yabe D; Yamamoto F; Lund SS; Okamura T; Kadowaki T
    Expert Opin Drug Saf; 2022 Oct; 21(10):1303-1313. PubMed ID: 35418260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
    Sarashina A; Friedrich C; Crowe S; Patel S; Graefe-Mody U; Hayashi N; Horie Y
    J Diabetes Investig; 2016 Sep; 7(5):744-50. PubMed ID: 27180969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Ledesma G; Umpierrez GE; Morley JE; Lewis-D'Agostino D; Keller A; Meinicke T; van der Walt S; von Eynatten M
    Diabetes Obes Metab; 2019 Nov; 21(11):2465-2473. PubMed ID: 31297968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 20. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.